Figure 6
The differential presence of tryptophan-derived metabolites (A–F) and the bacterial taxa correlated with metabolite (indicated in panel upper label) concentration (G–J) in each treatment group. Many tryptophan-derived metabolites were differentially present due to BMD treatment. The bacterial taxa with significant correlation with these metabolites (q value < 0.05, rho >0.5) were generally distinct between the control and therapeutic groups, while there was some overlap between the subtherapeutic group and the other two treatment groups. ctrl, no antibiotic control; sub, subtherapeutic BMD dose; ther, therapeutic BMD dose. The tryptophan degradation pathway (K) is provided for reference.
